HHS and White House Launch Clinical AI Standards Sprint with Closed-Door Industry Demos
核心洞察
The White House OSTP, FDA, and ONC are convening experts for a one-month "sprint" to develop consensus principles for clinical AI benchmarking and evaluation.
Federal regulators held a closed-door "clinical AI demo day" on July 8 at FDA headquarters with 10 companies including Microsoft AI (搜索), Amazon One Medical (搜索), and Anthropic (搜索).
The initiative aims to help officials gain firsthand experience with AI doctor technology while shaping regulatory and payment policy for health AI.
The White House and the Department of Health and Human Services are mounting a coordinated push to establish standards for clinical artificial intelligence, combining a formal expert "sprint" with closed-door industry demonstrations aimed at giving regulators firsthand exposure to AI doctor technology.
According to an invitation reviewed by STAT, the White House's Office of Science and Technology Policy (OSTP), the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will convene experts to discuss benchmarking and evaluation of clinical AI. The goal is to arrive at "a consensus set of principles" through a one-month sprint broken into a written phase and a discussion phase.
The initiative reflects growing urgency among federal health officials to safely accelerate adoption of clinical AI while establishing guardrails for its evaluation and use.
Closed-Door Demo Day Brings Industry to the Table
In parallel with the expert sprint, federal regulators hosted a "clinical AI demo day" on July 8 at the FDA's White Oak headquarters. Officials from the FDA and the Centers for Medicare and Medicaid Services (CMS) met with leaders from 10 companies, according to an agenda reviewed by STAT.
The participating companies spanned a broad cross-section of the health AI landscape: Anthropic (搜索), Counsel Health (搜索), Curai (搜索), K Health (搜索), Microsoft AI (搜索), Amazon One Medical (搜索), Doctronic (搜索), Ellipsis Health (搜索), Hippocratic AI (搜索), and Welldoc (搜索).
STAT spoke with four companies that attended — Counsel Health (搜索), K Health (搜索), Hippocratic AI (搜索), and Ellipsis Health (搜索) — whose leaders summarized their comments to regulators. The meeting was designed to offer federal health officials firsthand experience with AI doctor technology as it exists today.
Policy Implications for a Rapidly Evolving Field
For the assembled companies, which included powerful technology giants as well as startups funded by influential investors such as Andreessen Horowitz and Khosla Ventures, the event offered a significant opportunity to help shape policy as officials wrestle with regulating health AI and determining how to pay for it.
The dual-track approach — combining expert consensus-building with direct industry engagement — signals that federal regulators are seeking both scientific rigor and practical understanding as they develop frameworks for clinical AI oversight.